Clinical translation of controlled protein delivery systems for tissue engineering
- PMID: 25787736
- PMCID: PMC4311895
- DOI: 10.1007/s13346-013-0135-1
Clinical translation of controlled protein delivery systems for tissue engineering
Abstract
Strategies that utilize controlled release of drugs and proteins for tissue engineering have enormous potential to regenerate damaged organs and tissues. The multiple advantages of controlled release strategies merit overcoming the significant challenges to translation, including high costs and long, difficult regulatory pathways. This review highlights the potential of controlled release of proteins for tissue engineering and regenerative medicine. We specifically discuss treatment modalities that have reached preclinical and clinical trials, with emphasis on controlled release systems for bone tissue engineering, the most advanced application with several products already in clinic. Possible strategies to address translational and regulatory concerns are also discussed.
Figures
References
-
- Jaklenec A, et al. Progress in the tissue engineering and stem cell industry "are we there yet?". Tissue Eng Part B Rev. 2012;18(3):155–166. - PubMed
-
- Medtronic. Medtronic INFUSE® Bone Graft + LT-CAGE® Lumbar Tapered Fusion Device Fact Sheet. 2012 http://wwwp.medtronic.com/Newsroom/LinkedItemDetails.do?itemId=110176922....
-
- Betz VM, et al. Bone tissue engineering and repair by gene therapy. Front Biosci. 2008;13:833–841. - PubMed
-
- Dang JM, Leong KW. Natural polymers for gene delivery and tissue engineering. Adv Drug Deliv Rev. 2006;58(4):487–499. - PubMed
-
- Place ES, Evans ND, Stevens MM. Complexity in biomaterials for tissue engineering. Nature Materials. 2009;8(6):457–470. - PubMed
Publication types
MeSH terms
Substances
Grants and funding
LinkOut - more resources
Full Text Sources
Other Literature Sources
